Boc-NH-CH2-[(2-(amino(hydroxylimino)methyl))5-pyridinyl] | 633336-77-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Boc-NH-CH2-[(2-(amino(hydroxylimino)methyl))5-pyridinyl]
• 英文别名: Boc-NH-CH₂-[(2-(amino(hydroxylimino)methyl))5-pyridinyl]
• CAS: 633336-77-3
• 化学式: C₁₂H₁₈N₄O₃
• 分子量: 266.3
• InChiKey: SJYOJKSAQSSFKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  109.83
• 氢给体数：
  3.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  Boc-NH-CH2-[(2-(amino(hydroxylimino)methyl))5-pyridinyl] 在 乙酸酐 、 N,N-二异丙基乙胺 、 palladium 10% on activated carbon 、 氢气 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 溶剂黄146 为溶剂， 反应 13.5h， 以0.12 g的产率得到5-(aminomethyl)pyridine-2-carboximidamide
  参考文献：
  名称：

  Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue

  摘要：

  Paired basic amino acid cleaving enzyme 4 (PACE4), a serine endoprotease of the proprotein convertases family, has been recognized as a promising target for prostate cancer. We previously reported a selective and potent peptide based inhibitor for PACE4, named the multi-Leu peptide (Ac-LLLLRVKR-NH2 sequence), which was then modified into a more potent and stable compound named C23 with the following structure: Ac-DLeu-LLLRVK-Amba (Amba: 4-amidinobenzylamide). Despite improvements in both in vitro and in vivo profiles of C23, its selectivity for PACE4 over furin was significantly reduced. We examined other Argmimetics instead of Amba to regain the lost selectivity. Our results indicated that the replacement of Amba with 5-(aminomethyl)picolinimidamide increased affinity for PACE4 and restored selectivity. Our results also provide a better insight on how structural differences between 51 pockets of PACE4 and furin could be employed in the rational design of selective inhibitors.

  DOI：

  10.1021/acs.jmedchem.8b01381
• 作为产物：
  描述：

  6-氰基吡啶-3-甲酸甲酯 在 sodium tetrahydroborate 、 偶氮二甲酸二异丙酯 、 盐酸羟胺 、 potassium carbonate 、 一水合肼 、 N,N-二异丙基乙胺 、 三苯基膦 、 lithium chloride 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 水 为溶剂， 反应 56.5h， 生成 Boc-NH-CH2-[(2-(amino(hydroxylimino)methyl))5-pyridinyl]
  参考文献：
  名称：

  Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue

  摘要：

  Paired basic amino acid cleaving enzyme 4 (PACE4), a serine endoprotease of the proprotein convertases family, has been recognized as a promising target for prostate cancer. We previously reported a selective and potent peptide based inhibitor for PACE4, named the multi-Leu peptide (Ac-LLLLRVKR-NH2 sequence), which was then modified into a more potent and stable compound named C23 with the following structure: Ac-DLeu-LLLRVK-Amba (Amba: 4-amidinobenzylamide). Despite improvements in both in vitro and in vivo profiles of C23, its selectivity for PACE4 over furin was significantly reduced. We examined other Argmimetics instead of Amba to regain the lost selectivity. Our results indicated that the replacement of Amba with 5-(aminomethyl)picolinimidamide increased affinity for PACE4 and restored selectivity. Our results also provide a better insight on how structural differences between 51 pockets of PACE4 and furin could be employed in the rational design of selective inhibitors.

  DOI：

  10.1021/acs.jmedchem.8b01381

文献信息

• Mandelic acid derivatives and their use as throbin inhibitors
  申请人：——

  公开号：US20040019033A1

  公开（公告）日：2004-01-29

  There is provided a compound of formula I 1 wherein R a , R 1 , R 2 , Y and R 3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了一种公式I的化合物 1 其中R a , R 1 , R 2 , Y和R 3 具有说明书中给出的含义以及药学上可接受的衍生物（包括前药），这些化合物和衍生物可用作竞争性胰蛋白酶样蛋白酶抑制剂，如凝血酶，因此，特别是用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• [EN] PHARMACEUTICAL COMBINATION<br/>[FR] COMBINAISON PHARMACEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2003101956A1

  公开（公告）日：2003-12-11

  There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

  提供了一种组合产品，包括：(1) WO 02/44145中权利要求1的化合物或WO 02/44145中权利要求20的化合物（或其衍生物）或药用可接受的衍生物；以及（1）WO 01/28992中权利要求1定义的化合物或（2）WO 01/28992中权利要求34的化合物或（3）化合物A或B或C或D（或药用可接受的盐）用于治疗心律不齐或其凝血控制的并发症。